Abstract:Background and Aims: Ovarian carcinoma (OC) is one of the most lethal malignant tumors with a high reoccurrence and chemoresistance. The key mechanism relationship with chemoresistance in ovarian carcinoma is still unclear. The existence of cancer stem cells involves in chemoresistance and reoccurrence in OC. The objective of this study was to investigate the expression, suppression of malignant properties and reversal of paclitaxel resistance inhibiting RNA-binding protein Musashi-1 with siRNA in ovarian cancer cells. Methods: The expression of MSI-1 was analyzed in 39 normal ovarian epithelia tissues, 92 serous cystadenomas, 68 borderline serous cystadenomas, and 97 serous cystadenocarcinomas by immunohistochemistry. pLKO.1-MSI-1-siRNA expression vector was transfected into ovarian carcinoma cell line A2780 and its paclitaxel-resistant cell subline A2780/Taxol. The roles of MSI-1 in proliferation, apoptosis, migration and invasion were explored by cell proliferation analysis, Caspase 3 activity assay, wound healing assay, migration and matrigel invasion assay, respectively. Western Blotting and Real-time quantitative PCR were conducted to detect the expression of MSI-1 and the ERK signaling pathway. Reversal of paclitaxel resistance assay was used to evaluate the role of MSI-1 in paclitaxel resistance of OC cells. Finally, therapeutic effects of MSI-1 inhibition were investigated the xenogratfs of SCID mice in vivo of the paclitacel-resistant. Results: MSI-1 is overexpressed and associated with an unfavorable prognosis in OC patients. Knockdown of MSI-1 by small interfering RNA (siRNA) inhibits proliferation, promotes apoptosis, and reduces migration and invasion of cancer cells. Moreover, MSI-1 expression inhibition reverses paclitaxel-resistance in OC cells. We further display that MSI-1 effectively protects OC cells from paclitaxel-induced apoptosis by increasing the expression of p-Bcl-2 through ERK signaling pathway activation. In vivo, MSI-1 siRNA clearly showed a strong effect on tumor growth inhibition and paclitaxel-resistance reversal. Conclusions: These findings suggest that MSI-1 overexpression is associated with the prognosis of OC patients, and knockdown of MSI-1 can suppress malignant properties and reverse paclitaxel-resistance in OC cells. MSI-1 maybe act as a potential prognostic indicator and a therapeutic target in OC.

Inhibiting Proliferation and Enhancing Chemosensitivity to Taxanes in Osteosarcoma Cells by RNA Interference-Mediated Downregulation of Stathmin Expression

Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS

Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma

MicroRNA-1236-3p Inhibits Human Osteosarcoma Growth

Synergistically enhancive effect of stathmin gene silencing on sensitivity of LM8 cells to docetaxel in vitro

Decrease in stathmin expression by arsenic trioxide inhibits the proliferation and invasion of osteosarcoma cells via the MAPK signal pathway

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

Stathmin is Key in Reversion of Doxorubicin Resistance by Arsenic Trioxide in Osteosarcoma Cells.

Thiostrepton and Mir-216B Synergistically Promote Osteosarcoma Cell Cytotoxicity and Apoptosis by Targeting FoxM1

Rnai-Mediated Knockdown Of Erk1/2 Inhibits Cell Proliferation And Invasion And Increases Chemosensitivity To Cisplatin In Human Osteosarcoma U2-Os Cells In Vitro

Silencing Stathmin Gene Expression by Survivin Promoter-Driven Sirna Vector to Reverse Malignant Phenotype of Tumor Cells.

Overexpression of Stathmin 1 Leads to Docetaxel Based Induction Chemotherapy Resistance Via Mutant P53 in Oral Squamous Cell Carcinoma

Stathmin Guides Personalized Therapy in Oral Squamous Cell Carcinoma.

A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells

MicroRNA-22 Inhibits the Proliferation and Migration, and Increases the Cisplatin Sensitivity, of Osteosarcoma Cells

Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin.

Construction of Sirna Expression Vectors Targeting Stathmin and Its Influcence on Biological Behaviour in LM8 Cells

RNA‐binding Protein PUM2 Suppresses Osteosarcoma Progression Via Partly and Competitively Binding to STARD13 3′UTR with Mirnas

RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma

Small Interfering RNA-mediated Silencing of G-protein-coupled Receptor 137 Inhibits Growth of Osteosarcoma Cells

[Therapeutic Effects of Small Interfering RNA Targeting MDM2 on Human Osteosarcoma Cells].